ISRG
Intuitive Surgical, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Oct. 18, 4:30 PM
    • Intuitive Surgical (NASDAQ:ISRG) Q3 results ($M): Total Revenues: 682.9 (+1.9%); Instruments & Accessories: 348.1 (+2.6%); Systems: 205.1 (+1.2%); Services: 129.7 (+1.2%).
    • Net Income: 211.0 (+14.4%); Non-GAAP Net Income: 245.7 (+11.3%); EPS: 5.31 (+12.7%); Non-GAAP EPS: 6.19 (+10.1%).
    • Da Vinci shipments: 134 (+16.5%).
    • Shares are up 1% after hours on average volume.
    | Tue, Oct. 18, 4:30 PM
  • Tue, Oct. 18, 4:06 PM
    • Intuitive Surgical (NASDAQ:ISRG): Q3 EPS of $6.19 beats by $1.06.
    • Revenue of $682.9M (+15.8% Y/Y) beats by $32.41M.
    • Shares +1.56%.
    • Press Release
    | Tue, Oct. 18, 4:06 PM | 4 Comments
  • Mon, Oct. 17, 5:35 PM
    | Mon, Oct. 17, 5:35 PM | 9 Comments
  • Fri, Sep. 2, 7:52 AM
    • Athenahealth (NASDAQ:ATHN) initiated with Hold rating by Stifel Nicolaus.
    • Juno Therapeutics (NASDAQ:JUNO) initiated with Sell rating and $23 (15% downside risk) price target by BTIG Research. Initiated coverage on Kite Pharma (NASDAQ:KITE) with Neutral rating.
    • Gemphire Therapeutics (Pending:GEMP) initiated with Buy rating and $17 (26% upside) price target by Canaccord Genuity. Initiated with Outperform rating and $25 (86% upside) price target by RBC Capital.
    • Galapagos NV (NASDAQ:GLPG) initiated with Buy rating and $64 (18% upside) price target by Janney Capital.
    • Sophiris Bio (NASDAQ:SPHS) initiated with Overweight rating and $7 (138% upside) price target by Piper Jaffray.
    • Cantel Medical (NYSE:CMN) initiated with Buy rating and $83 (9% upside) price target by Benchmark.
    • Recro Pharma (NASDAQ:REPH) initiated with Buy rating and $21 (122% upside) price target by Janney Montgomery Scott.
    • Theravance Biopharma (NASDAQ:TBPH) initiated with Buy rating and $41 (42% upside) price target by Evercore ISI.
    • Intuitive Surgical (NASDAQ:ISRG) initiated with Outperform rating by Raymond James.
    | Fri, Sep. 2, 7:52 AM
  • Tue, Jul. 26, 1:13 PM
    • "We see an obvious flaw in this analysis," says David Einhorn in his Q2 letter to Greenlight Capital investors. He's referring to Andrew Left's Citron's short of Chemours (CC +8.5%). Left contended Chemours could face $5B in liabilities thanks to 3.5K lawsuits from people living near its Teflon plant in Parkersburg, WV. Double-checking with Left, Einhorn found no math to justify that lofty figure.
    • Others have pegged the liability at just several hundred million dollars, not enough to topple the company.
    • Greenlight is an owner of 8.8M shares as of March 31.
    • In other Greenlight news, the hedge fund took advantage of the post-Brexit panic to cover shorts against Intuitive Surgical (ISRG +0.2%), Under Armour (UA -5.8%), and United Rentals (URI +2.3%).
    • Longs sold out of include: American Capital Agency (AGNC +0.4%), Baxter International (BAX +3.3%), Ingram Micro (IM -0.7%), and Oil States International (OIS +0.7%).
    • Greenlight fell 2.6% in Q2, bringing it nearly back to break-even for the year.
    | Tue, Jul. 26, 1:13 PM | 15 Comments
  • Tue, Jul. 19, 5:36 PM
    | Tue, Jul. 19, 5:36 PM | 5 Comments
  • Tue, Jul. 19, 4:21 PM
    • Intuitive Surgical (NASDAQ:ISRG) Q2 results ($M): Total Revenues: 670.1 (+14.3%); Instruments And Accessories: 339.3 (+14.3%); Systems: 202.7 (+15.2%); Services: 128.1 (+13.1%).
    • Net Income: 184.5 (+37.2%); Non-GAAP Net Income: 220.4 (+27.5%); EPS: 4.71 (+32.3%); Non-GAAP EPS: 5.62 (+23.0%).
    • Da Vinci shipments: 15 (+200.0%).
    • Shares are up 5% after hours on increased volume.
    | Tue, Jul. 19, 4:21 PM | 2 Comments
  • Tue, Jul. 19, 4:07 PM
    • Intuitive Surgical (NASDAQ:ISRG): Q2 EPS of $5.62 beats by $0.65.
    • Revenue of $670M (+14.3% Y/Y) beats by $29.31M.
    • Shares +3.7%.
    • Press Release
    | Tue, Jul. 19, 4:07 PM
  • Mon, Jul. 18, 5:35 PM
    | Mon, Jul. 18, 5:35 PM | 1 Comment
  • Fri, Jun. 3, 8:17 AM
    • Ophthotech (NASDAQ:OPHT) upgraded to Overweight from Neutral by JPMorgan. Price target raised to $84 (45% upside) from $60.
    • Intuitive Surgical (NASDAQ:ISRG) downgraded to Neutral from Buy by Goldman Sachs. Price target raised to $674 (5% upside) from $633.
    • Celgene (NASDAQ:CELG) downgraded to Neutral from Buy by BTIG Research.
    • Medtronic (NYSE:MDT) downgraded to Neutral from Buy by BTIG Research. $82 price target removed.
    • Portola Pharmaceuticals (NASDAQ:PTLA) downgraded to Neutral from Outperform by Credit Suisse. Price target lowered to $30 (7% upside) from $33.
    | Fri, Jun. 3, 8:17 AM | 5 Comments
  • Tue, Apr. 19, 4:30 PM
    • Intuitive Surgical (NASDAQ:ISRG) Q1 results ($M): Total Revenues: 594.5 (+11.7%); Systems: 147.9 (+4.9%); Services: 124.5 (+9.3%).
    • Net Income: 136.4 (+40.6%); Non-GAAP Net Income: 170.3 (+26.5%); EPS: 3.54 (+37.7%); Non-GAAP EPS: 4.42 (+23.8%).
    • Da Vinci system shipments: 110 (+11.1%).
    • Shares are up 2% after hours on increased volume.
    | Tue, Apr. 19, 4:30 PM
  • Tue, Apr. 19, 4:06 PM
    • Intuitive Surgical (NASDAQ:ISRG): Q1 EPS of $4.42 beats by $0.09.
    • Revenue of $594.5M (+11.7% Y/Y) beats by $1.42M.
    • Shares -3%.
    | Tue, Apr. 19, 4:06 PM
  • Mon, Apr. 18, 5:35 PM
    | Mon, Apr. 18, 5:35 PM | 4 Comments
  • Fri, Apr. 1, 11:25 AM
    • Cepheid (CPHD +6%) upgraded to Buy from Neutral by BTIG Research. Price target set at $42 (19% upside).
    • Cardiovascular Systems (CSII +28.1%) upgraded to Buy from Underperform by Needham. Price target set at $16 (20% upside).
    • United Health Services (UHS -0.6%) upgraded to Outperform from Market Perform by Wells Fargo.
    • PRA Health Services (PRAH +1.4%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey. Price target raised to $51 (17% upside) from $47.
    • Dimension Therapeutics (DMTX +3.1%) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $10 (25% upside) from $12.
    • Novartis (NVS -2%) downgraded to Neutral from Buy by UBS. Price target lowered to CHF72 (3% upside) from CHF100. Downgraded to Neutral from Buy by Citigroup.
    • Intuitive Surgical (ISRG -0.2%) downgraded to Neutral from Buy by BTIG Research.
    • ATyr Pharma (LIFE -1%) downgraded to Market Perform from Outperform by William Blair. Price target lowered to $8 (106% upside) from $42.
    • Achaogen (AKAO -1.4%) downgraded to Market Perform from Outperform by Cowen & Co.
    • Portola Pharmaceuticals (PTLA +4.1%) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $30 (40% upside) from $65.
    • Quintiles Transnational Holdings (Q +1.9%) downgraded to Neutral from Buy by SunTrust Robinson Humphrey.
    | Fri, Apr. 1, 11:25 AM | 1 Comment
  • Mon, Mar. 28, 9:08 AM
    • TransEnterix (NYSEMKT:TRXC) is down 10% premarket on light volume in response to its announcement that it now expects to receive the FDA's decision on its 510(k) application for its robotic surgery system, SurgiBot, by mid-April. It had expected to receive notification in Q1.
    • The review clock for a 510(k), a regulatory pathway with a lower bar for approval than a PMA (pre-market approval), is usually ~six months. The company submitted its application on or about June 1, 2015 so the agency's review is already tardy, increasing that risk that there could be deficiencies in the filing that could delay clearance.
    • The single-port Surgibot system allows the surgeon to be in the sterile field which means he/she can stand beside the patient rather than sit behind a console like Intuitive Surgical's (NASDAQ:ISRGda Vinci system. It also features a combination of reusable and disposable instruments.
    • Previously: TransEnterix moving closer to launch of SurgiBot System; shares down 18% premarket on profit taking (Feb. 10)
    | Mon, Mar. 28, 9:08 AM | 16 Comments
  • Mon, Mar. 14, 10:32 AM
    • Intuitive Surgical (ISRG +1.3%) receives 510(k) clearance for its da Vinci Xi EndoWrist Stapler 30 (30 mm)  instruments and reloads. Stapler 30 expands the EndoWrist portfolio with new curved and straight tip devices and four reloads for use in general, thoracic, gynecologic and urologic surgery.
    • The da Vinci Xi Surgical System enables the control of stapling from the surgeon console. The EndoWrist Stapler has the greatest side-to-side articulation currently available, with a range of 108 degrees, plus up-and-down articulation up to 54 degrees.
    • The Stapler 30 rollout will commence immediately.
    | Mon, Mar. 14, 10:32 AM | 1 Comment